4 Pharmaceutical Stocks to Buy Now

PATH, WPI, IPXL, MYL improve in weekly rankings

   
4 Pharmaceutical Stocks to Buy Now

Four pharmaceutical stocks are moving up in their overall rating this week, according to the Portfolio Grader database. Every one of these is graded an “A” (“strong buy”) or “B” overall (“buy”).

NuPathe Inc. (PATH) is bettering its rating of C (“hold”) from last week to a B (“buy”) this week. NuPathe develops pharmaceutical products used for the treatment and management of neurological and psychiatric diseases. In Portfolio Grader’s specific subcategories of Earnings Momentum and Earnings Revisions, PATH also gets A’s. For more information, get Portfolio Grader’s complete analysis of PATH stock.

This week, Watson Pharmaceuticals (WPI) is making solid headway. The company’s rating improves to an A (“strong buy”) from last week’s B (“buy”) rating. Watson develops, manufactures, markets, sells and distributes pharmaceutical products. For more information, get Portfolio Grader’s complete analysis of WPI stock.

This week, Impax Laboratories, Inc.’s (IPXL) ratings are up from a C last week to a B. Impax Laboratories develops, manufactures, and markets both proprietary and multi-source pharmaceutical products utilizing its drug delivery technologies. For more information, get Portfolio Grader’s complete analysis of IPXL stock.

Mylan (MYL) earns an A this week, jumping up from last week’s grade of B. Mylan is a global generic and specialty pharmaceuticals company. For more information, get Portfolio Grader’s complete analysis of MYL stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, http://investorplace.com/2014/07/4-pharmaceutical-stocks-to-buy-now-path-wpi-ipxl-8/.

©2014 InvestorPlace Media, LLC

Comments are currently unavailable. Please check back soon.